Abstract: The aim of this study was first, to evaluate the effects of continuous hemodiafiltration (CHDF) alone or combined with CHDF and polymyxin-B immobilized fiber (PMX) on survival rates of patients with sepsis and acute renal failure, and second, to evaluate the changes in plasma levels of inflammatory cytokines before and after treatment with CHDF and PMX and CHDF alone in these patients. Forty-eight patients with septic shock and acute renal failure were enrolled in this study. The survival rate of all patients at 28 days was 25% for those with CHDF and 75% for those with PMX and CHDF treatment. Com bination treatment produced a significant reduction of plasma levels of endotoxin and interleukin-6 compared to the basal values and to the treatment with CHDF alone. From these data, it is suggested that the combined therapy with PMX and CHDF is effective in improvement of sur vival rate of patients with septic shock and acute renal failure.
(MOF) (10,ll) . However, data from experimental and clinical studies have been inconsistent and some times contradictory (12) . During sepsis, release of various endotoxins from microorganisms activates immune cascade systems including release of anti-and proinflammatory cyto kines. As described above, these cytokines might be removed with CHF; however, it remains uncertain whether endotoxins are removed effectively with CHF (13) . Recently, immobilized polymyxin-B fi bers (PMXs), which were developed to remove en dotoxin selectively, have been available clinically in Japan (14, 15) . This newly developed technique pro vides some successful results (16, 17) . These 2 techniques listed above seem to be effec tive for treatment of critically ill patients with sepsis and acute renal failure (ARF). However, whether and to what extent combined PMX treatment and CHF provides interaction effects for the prognosis of these patients remains unexplored. In the present study, we undertook to compare the efficacy of CHF and its combination with PMX for prognosis of critically ill patients with sepsis and ARF in a prospective randomized open trial. To do 234 this, we compared and analyzed plasma from pa tients with sepsis who had received CHF alone or its combination with PMX. We focused on those me diators (endotoxin, inteiieukin (IL)-IB, and IL-6) that are believed to play a pivotal role in the patho physiology of sepsis.
METHODS

Patients
Patients with a clinical diagnosis of septic shock as defined by the American College of Chest Physi cians/Society of Critical Care Medicine Consensus Conference (18) and ARFas defined by a rise ofthe serum creatinine 0.5 mg/dl daily and a urine output less than 20 ml/h despite volume correction and in tensive diuretic therapy were enrolled in the study. Informed consent was obtained from a close family member. Patients who were less than 18 years old, pregnant, and organ-transplant recipients were not enrolled. Patients were not eligible if informed con sent from the patient's family was not granted, if they were experiencing acute organ transplant rejec tion, or if they were in a chronic vegetative state. Decisions concerning supportive care and surgical intervention were made by the patients' attending physicians and were not dictated by the study pro tocol.
Evaluation of the patients Patients were followed for 28 days or until death. An APACHE II score was calculated at entry. Pa tients were stratified for the severity of illness at baseline according to the overall APACHE II score (19) . The primary source of infection, causative patho gen, and adequacy of antimicrobial therapy were de termined in a blinded fashion by a specialist in the microbiology section. Gram-negative sepsis was considered to be pre sent at study entry when a culture of blood or body fluid from a site of suspected infection obtained from 2 days before through 2 days after the day of study entry grew a gram-negative organism. In a small number of patients, no infection site had been found despite an aggressive search for bacterial infection. However, in those patients, gram-negative infection was suspected mostly on the basis of high fever and increased number of white blood cells count with a left shift of differential count.
Study design All patients receiving a regular antibiotic therapy and other supportive treatment including continuous venovenous hemodiafiltration (CHDF) were assigned randomly to a group with or without PMX treatment. The primary end points were mortality from all causes; at Day 28 after the PMX procedure and if patients were discharged from the hospital or transferred to another hospital within 28 days. The outcomes were ascertained by the patients' attend ing physicians.
Continuous venovenous hemodiafiltration Vascular access was obtained via a double-lumen hemodialysis catheter (Vas-cath; Salt Lake City, UT, U.S.A.) into either the femoral orjugular vein (6, 13) . CHDF was performed using the PMMA dialyzer (Toray Co., Tokyo, Japan) that contains a highly permeable polymethylmethacrylate membrane. Blood was pumped by a peristaltic pump with pres sure alarms and air trap (JUN-500; Ubejunnkenn Co., Tokyo, Japan), at a rate of 100 to 150 ml/min, from the arterial lumen of the catheter through the hemo filter and back into the circulation via the ve nous lumen of the catheter. Dialysate was delivered to the filter and ultrafiltrate collected as in CHDF. A balanced and isotonic electrolyte solution (HF solita; Shimizu Co., Shizuoka, Japan) was infused through the efferent limb of the extracorporal system to maintain zero fluid balance. A steady state rate of 1 L of ultrafiltrate per hour (approximately 20 ml/kg/ min) and isovolumetric fluid replacement were achieved. An electrolyte solution was warmed to 38°C and infused in a postdilution mode to maintain a zero fluid balance. The anticoagulant was nafamo stat mesilate (Torii Co., Ltd., Tokyo, Japan), and the usual doses were between 30 and 50 mg/h. The acti vated clotting time (ACT) was measured every 3 h, and the doses of nafamostat mesilate were adjusted to maintain the ACT around 150 s. When the ACT was more than 180 s, the administration of nafamo stat mesilate was withdrawn transiently until the ACT approached around 150 s. After 12 to 24 h, the hemo filter was regularly replaced during CHDF. Direct hemoperfusion for polymyxin-B immobilized fiber treatment Direct hemoperfusion was carried out for 4 h at a flow rate of 100 ml/min through a venovenous cath eter used for CHDF as before' (14, 17) . During PMX treatment, CHDF was discontinued. All entry crite ria were met within a 12 h period, and the PMX or CHDF was started within the next 8 h. In combina tion therapy, after the end of 4 h PMX treatment, CHDF was started. CHDF was continued at least for the next 24 h or until death. In addition, CHDF was discontinued when ARF was recovered. Collection of plasma Blood samples were obtained before the initiation of PMX treatment or CHDF and after these treat ments. Blood samples were obtained at 6 h and 24 h after the initiation of the treatment. Immediately af ter collection, all plasma tubes were centrifuged at 4°C for 15 min and stored at -80°C until measure ments.
Measurement of endotoxin Serum endotoxin was assayed for endotoxin by the Endospecy method (14) . The normal upper limit was 9.8 pg/ml (14) . Determinations of cytokines Plasma IL-1(3 was measured by enzyme-linked im munosorbent assay (ELISA) according to the manu facturer's instructions. This assay detected only IL-1 (3, and the lower limit of detection in our laboratory was 20 pg/ml. Plasma IL-6 was measured using an ELISA ac cording to the manufacturer's instructions. This as say detected only IL-6, and the lower limit of detec tion in our laboratory was 20 pg/ml. Table 2 . Antibiotic therapy was judged to be adequate when the patient received an antibi otic to which each isolated organism was sensitive. The survival rate of all patients at 14 days was 25% for those with CHDF and 75% for those with PMX and CHDF treatment, and these were main tained at the end of the study (Fig. 1) . At the end of the study, 3 patients in PMX and CHDF treatment and 4 patients in CHDF remained on hemodialysis therapy. Between these 2 groups, there was a signifi cant difference in survival rate (p < 0.01).
Effects of continuous hemodiafiltration with polymyxin-B immobilized fiber treatment and continuous hemodiafiltration on blood pressure and biochemical findings Treatment with PMX and CHDF in combination increased blood pressure from 78 ± 2 to 94 ± 4 mm Hg (p < 0.001) at 24 h after the start of treatment. However, treatment with CHDF alone did not change the mean blood pressure (75 ± 3 to 75 ± 4mm Hg). There were no significant differences between the 2 groups ( Table 3) . Dose of dopamine Patients treated with CHDF only needed a rela tively larger dose of dopamine at the end of the treatment. On the other hand, patients treated with PMX and CHDF did not receive the increases of the dose of dopamine (Fig. 2) .
Adverse effects of polymyxin-B immobilized fiber treatment There were no serious adverse effects of PMX treatment throughout the study. Serum levels of endotoxin At the start, there were no significant differences in endotoxin levels between these 2 groups. Treat ment with PMX and CHDF in combination signifi cantly reduced plasma levels of endotoxin; however, CHDF reduced it without significance (Fig. 3) . Changes in cytokines Plasma levels of IL-6 were decreased significantly by CHDF and its combination with PMX (Fig. 4) . Plasma levels of IL-ip were significantly lowered by CHDF and its combination with PMX (Fig. 5) .
DISCUSSION
In the present study, we compared the effects of the 2 kinds of treatments, CHDF and its combina tion with PMX, on outcome of patients with the sep- CHDF  FIG. 2 . Changes in the dose of dopamine for support of circula tory failure in patients with septic shock before, during, and after treatment with PMX and CHDF or CFIDF alone is shown. Com bination treatment produced a significant reduction of dose of dopamine at 24 h treatment compared to treatment with CHDF alone. **p < 0.01 compared to CHDF (PMX: polymyxin-B immo bilized fiber, CHDF: continuous hemodiafiltration).
sis syndrome. In all patients enrolled in this study, the combination of CHDF and PMX had more ben eficial effects on outcomes of patients with sepsis syndrome. Our previous study demonstrated that the treatment with PMX was effective in patients with APACHE II scores between 20 and 25 (23, 24) . Meloni et al. (25) have demonstrated that CHDF is useful in septic patients to correct fluid overload and ARF, without affecting hemodynamic stability and oxygen balance. These results raise a possibility that this technique will improve the prognosis of sep tic patients complicated with ARF. In addition to these beneficial advantages, another potential ben efit of hemofiltration is to remove a number of pro inflammatory mediators that may be involved in the development of MOF (12, 26) . During sepsis, proinflammatory cytokines, par ticularly, IL-1, IL-6, and IL-8 are released in exces sive quantities from activated macrophages. This cy tokine response is regulated by the intricate network CHDF  FIG. 4 . The graph shows changes in plasma levels of inlerleukin (IL)-6 before and after treatmentwtih PMXand CHDForCHDF alone. Both combination treatment with PMX and CHDF and with CHDF alone reduced significantly plasma levels of IL-6, and at 24 h there was a significant difference between these 2 treat ments (+p <0.05 and ++p <0.01 compared to the basa! valuesand i:p < 0.05 compared to CHDF alone) (PMX: polymyxin-B immo bilized fiber, CHDF, continuous hemodiafiltration).
of mediators, including antiinflammatory cytokines and other endogenous antagonists (27) . Combining this evidence, it is expected that CHDF will be useful for treatment of patients with the sepsis syndrome. However, data from experimental and clinical stud ies have been consistent and sometimes contradic tory (12) . This lack of consistency may come from clearance of a larger number of molecules in the circulation including mediators with more protective effects. We measured several cytokines that have been considered to be indicators of seventy of sepsis and organ failure. In the present study, 3 cytokines, IL 1(3, and IL-6 all were elevated when the therapeutic hemoperfusion/hemofiltration was started. After ap- plication of treatments, tumor necrosis factor-a did not show any significant changes. However, plasma levels of IL-ip were decreased with both types of treatments. Similarly, plasma levels of IL-6 were sig nificantly decreased with treatments. However, in the pathological process of the sepsis syndrome, a variety of pro-and antiinflammatory cytokines are released and affect each other. It is therefore un likely that the removal of 1 of various cytokines is a determinant for improvement of septic shock. In our studies, the plasma endotoxin, IL-6, and IL-1|3 all were elevated and those levels are similar
with the values reported previously. Moreover, Ca sey et al. (28) reported that the prognosis of patients with sepsis correlated with these plasma levels of the cytokines. Combined with these data it is indicated that the therapeutic procedures with CHDF and its combination with PMX might produce beneficial ef fects. Despite these beneficial effects of removal of cy tokines, CHDF did not improve the prognosis of pa tients. One of the other major factors except cyto kines is possibly endotoxin. Endotoxin is the most active and potent mediator stimulating various cellular responses resulting in septicshock. It should be kept in mind that the elimi nation of endotoxin effectively from the circulation in patients with sepsis-induced ARF and/or MOF is reasonable (12) . PMX has been developed selec tively to remove endotoxin and has been available clinically in Japan (29) . There is strong evidence that the septic state is due to a combination of direct and indirect effects of endotoxin. Endotoxin releases a vast array of mediators including pro-and antiin flammatory cytokines. Based on this concept, it is reasonable to remove and/or to antagonize endotox in for treating patients with sepsis and septic shock (30, 31) . In this study, the plasma levels of endotoxin were decreased significantly with CHDF and PMX but not with CHDF alone. In Japan, in the reports of Kodama et al. and Tani et al. in multicenter trials using PMX in patients with sepsis, this treatment decreased the plasma endotoxin concentration and reduced morbidity with improvement of parameters such as blood pressure and oxygen consumption in dex (32, 33) . Moreover, Ebihara et al. and Nakamura et al. provided supportive evidence that PMX treat ment produced a reduction of erythropoietin, IL-6, and endothelin (16, 34) .
In the present study, treatment without PMX did not increase blood pressure as the result of no re duction of intravenous administered doses of dopa mine. From these data, it would be expected that application of PMX might improve the prognosis in patients with the sepsis syndrome when PMX was combined with CHDF. This indicates that in patients with the sepsis syndrome removal of only cytokines does not improve the pathophysiological process of septic shock. Indeed, combination therapy with PMX and CHDF produced a significant improve ment of survival rate of patients with the sepsis syn drome. In our recent study (23, 24) , treatment with PMX alone improved the survival rate of patients with the sepsis syndrome. In that study, we evaluated the severity of the patients with the APACHE II score system and did not assess these patients as having sepsis, severe sepsis, and septic shock. The majority of patients with more than 30 points of APACHE II score should be classified as having septic shock instead of sepsis. It is therefore likely that in our recent report the prognoses of these pa tients presumably having septic shock were not im proved with PMX treatment. Combining our recent and current data, it is suggested that patients with sepsis be treated with PMX and patients with septic shock be treated with PMX and CHDF in combina tion. This kind of notion is partially agreed to by Jaber and Pereira (35) : that the early institution of PMX treatment may halt the sepsis syndrome at an early stage.
In-conclusion, although in patients with septic shock the sole removal of either cytokines or endo toxin did not produce beneficial effects, the com bined therapy with PMX and CHDF is effective in improvement of survival rate of these patients.
